|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR:A systematic literature review显示文摘AIM:To review literature on efficacy and safety of octreotide-long-acting repeatable(LAR)used at doses higher than the Food and Drug Administration(FDA)-approved 30 mg/mo for treatment of neuroendocrine tumors(NETs).METHODS:We searched Pub Med and Cochrane Library from 1998-2012,5 conferences(American Society of Clinical Oncology,Endocrine Society,European Neuroendocrine Tumor Society,European Society for Medical Oncology,North American Neuroendocrine Tumor Society)from 2000-2013 using Me SH and keyterms including neuroendocrine tumors,carcinoid tumor,carcinoma,neuroendocrine,and octreotide.Bibliographies of accepted articles were also searched.Two reviewers reviewed titles,abstracts,and full-length articles.Studies that reported data on efficacy and safety of≥30 mg/mo octreotide-LAR for NETs in human subjects,published in any language were included in the review.RESULTS:The search identified 1086 publications,of which 238 underwent full-text review(20 were translated into English);17 were included in the review.Studies varied in designs,subjects,octreotide-LAR regimens,and definition of outcomes.Eleven studies reported use of higher doses to control symptoms and tumor progression,although symptom severity and formal quality-of-life analysis were not quantitatively measured.Ten studies reported efficacy,describing 260 subjects with doses ranging from 40 mg/mo or 30 mg/3 wk up to 120 mg/mo.Eight studies reported expert clinical opinion that supported dose escalation of octreotide-LAR up to 60 mg/mo for symptom control and suggested increased doses may be effective at preventing tumor progression.Eight studies reported safety;there was no evidence of increased toxicity associated with doses of octreotide-LAR>30 mg/mo.CONCLUSION:As reported in this review,octreotide-LAR at doses>30 mg/mo is being prescribed for symptom and tumor control in NET patients.Furthermore,expert clinical opinion provided support for escalation of somatostatin analogs for refractory hormonal symptoms. | Michael S Broder David Beenhouwer Jonathan R Strosberg Maureen P Neary Dasha Cherepanov | 2015 | World Journal of Gastroenterology2015，21，6： | 8 |
| 2 | Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors显示文摘AIM:To evaluate systemic treatment choices in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors(PNETs)and provide consensus treatment recommendations.METHODS:Systemic treatment options for pancreatic neuroendocrine tumors have expanded in recent years to include somatostatin analogs,angiogenesis inhibitors,inhibitors of mammalian target of rapamycinand cytotoxic agents.At this time,there is little data to guide treatment selection and sequence.We therefore assembled a panel of expert physicians to evaluate systemic treatment choices and provide consensus treatment recommendations.Treatment appropriateness ratings were collected using the RAND/UCLA modified Delphi process.After studying the literature,a multidisciplinary panel of 10 physicians assessed the appropriateness of various medical treatment scenarios on a 1-9 scale.Ratings were done both before and after an extended discussion of the evidence.Quantitative measurements of agreement were made and consensus statements developed from the second round ratings.RESULTS:Specialties represented were medical and surgical oncology,interventional radiology,and gastroenterology.Panelists had practiced for a mean of15.5 years(range:6-33).Among 202 rated scenarios,disagreement decreased from 13.2%(26 scenarios)before the face-to-face discussion of evidence to 1%(2)after.In the final ratings,46.5%(94 scenarios)were rated inappropriate,21.8%(44)were uncertain,and30.7%(62)were appropriate.Consensus statements from the scenarios included:(1)it is appropriate to use somatostatin analogs as first line therapy in patients with hormonally functional tumors and may be appropriate in patients who are asymptomatic;(2)it is appropriate to use everolimus,sunitinib,or cytotoxic chemotherapy therapy as first line therapy in patients with symptomatic or progressive tumors;and(3)beyond first line,these same agents can be used.In patients with uncontrolled secretory symptoms,octreotide LAR doses can be titrated up to 60 mg every4 wk or up to 40 mg every 3 or 4 wk.CONCLUSION:Using the Delphi process allowed physician experts to systematically obtain a consensus on the appropriateness of a variety of medical therapies in patients with PNETs. | Jonathan R Strosberg George A Fisher Al B Benson Lowell B Anthony Bulent Arslan John F Gibbs Edward Greeno Renuka V Iyer Michelle K Kim William J Maples Philip A Philip Edward M Wolin Dasha Cherepanov Michael S Broder | 2015 | World Journal of Gastroenterology2015，21，8： | 2 |
| 3 | Prevention and Control of Influenza with Vaccines Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010显示文摘 | Fiore Anthony E Uyeki Timothy M Broder Karen Finelli Lyn Euler Gary L Singleton James A Iskander John K Wortley Pascale M Shay David K Bresee Joseph S Cox Nancy J | 2010 | MMWR. Morbidity and Mortality Weekly Report2010，，： | 1 |
| 4 | Impaired synthesis of polyclonal (non-paraprotein) immtmoglobulins by circulating lymphocytes from patients with multiple myeloma: role of suppressor ceils 显示文摘 | Broder S Humphrey R Durm M | 1975 | New Engl J Med1975，293，18： | 1 |
| 5 | The development of antiretroviraltherapy and its impact on the HIV - 1/AIDSpandemic 显示文摘 | Broder S | 2010 | Antiviral Res2010，85，1： | 1 |
| 6 | The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic显示文摘 | Broder S | 2010 | Antiviral Res2010，85，1： | 1 |
| 7 | Syntactic clustering of the web 显示文摘 | Broder A Z Glassman S C Manasse M S | 1997 | Computer Networks and ISDN Systems1997，29，8： | 1 |
| 8 | Comparison of long-term outcomes of myomectomy and uterine artery embolization显示文摘 | Goodwin S Chen G | 2002 | Obstet Gynecol2002，100，51： | 1 |
| 9 | Graph structure in the web显示文摘 | Broder A Kumar R Maghoul F Raghavan P Rajagopalan S Stata R Tomkins A Wiener J | 2000 | Computer Networks2000，33，： | 1 |
| 10 | Substituent Effect on the MesoSubstituted Porphyrins:Theoretical Screening of Sensitizer Candidates for Dye-Sensitized Solar Cells显示文摘 | MITSUYA H BRODER S | 2009 | J Phys Chem2009，113，10： | 1 |
| 11 | Graph structure in the Web 显示文摘 | Broder A Kumar Maghoul F Raghavan P Rajagopalan S Stata R Tomkins A WienerJ | 2000 | Computer Networks2000，33，： | 1 |
| 12 | The development of antiretroviral therapy and its impact on the HIV- 1/AIDS pandemic显示文摘 | Broder S | 2010 | Antiviral Res2010，85，1： | 1 |
| 13 | Experimental and numerical studies of the hydrodynamics in a bubble column 显示文摘 | Lain S Broder D Sommerfeld M | 1999 | Chemical Engineering Science1999，54，： | 1 |
| 14 | Granulomatous infectious diseases associated with tumor necrosis factor antagonists显示文摘 | Wallis R S Broder M S Wong J Y | | 0，，09： | 1 |
| 15 | FIGO classification system(PALM-COEIN)for causes of abnormal uterine bleeding in nongravid women of reproductive age显示文摘 | Malcolm G Munro Hilary OD Critchley Michael S Broder | 2014 | International Journal of Gynecology and Obstetrics2014，25，1： | 1 |
| 16 | Syntactic clustering of the web显示文摘 | Broder A Z Steven C G Mark S M | 1997 | Computer Networks and ISDN Systems Archive1997，29，8： | 1 |
| 17 | The development of antiretroviral therapy and its impact on the HIV-1/AIDS显示文摘 | Broder S | 2010 | Antiviral Res2010，85，1： | 1 |
| 18 | The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic显示文摘 | Broder S | | 0，，01： | 1 |
| 19 | Comparison of ling-term outcomes of myomectomy and uterine artery embolization显示文摘 | Broder MS Goodwin S Chen G | 2002 | Obstet Gynecol2002，100，： | 1 |
| 20 | Molecular foundations of cancer:new targets for intervention显示文摘 | Kap J E Broder S | 1995 | Nature medicion1995，，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员